TY - JOUR
T1 - Improved dissolution behavior of lipophilic drugs by solid dispersions
T2 - The production process as starting point for formulation considerations
AU - Srinarong, Parinda
AU - de Waard, Hans
AU - Frijlink, Henderik W.
AU - Hinrichs, Wouter L. J.
PY - 2011/9
Y1 - 2011/9
N2 - Introduction: Many new drug substances have low aqueous solubility which can cause poor bioavailability after oral administration. The application of solid dispersions is a useful method to increase the dissolution rate of these drugs and thereby improve their bioavailability. So far, several methods have been developed to prepare solid dispersions. To obtain a product with the desired attributes, both the formulation and production processes should be considered.Areas covered: The most currently used methods to produce solid dispersions, such as the fusion method, hot melt extrusion, spray drying, freeze drying and supercritical fluid precipitation, are reviewed in this paper. In addition, the physicochemical characteristics of the obtained solid dispersions are discussed.Expert opinion: Solid dispersions can be successfully prepared by simple fusion, hot melt extrusion, spray drying, freeze drying and supercritical fluid precipitation. Hot melt extrusion, spray drying and freeze drying are processes that can be applied for large scale production. The simple fusion method is not very suitable for large scale production, but is particularly suitable for screening formulations. The most recent method to produce sold dispersions is supercritical fluid precipitation. The process conditions of this method need extensive investigation, in particular in relationship with the selection of the type of carrier and/or solvent. Both processes and formulation aspects strongly affect the characteristics of solid dispersion products. Furthermore, application of crystalline solid dispersions is gaining increasing interest because they are thermodynamically more stable than amorphous solid dispersions.
AB - Introduction: Many new drug substances have low aqueous solubility which can cause poor bioavailability after oral administration. The application of solid dispersions is a useful method to increase the dissolution rate of these drugs and thereby improve their bioavailability. So far, several methods have been developed to prepare solid dispersions. To obtain a product with the desired attributes, both the formulation and production processes should be considered.Areas covered: The most currently used methods to produce solid dispersions, such as the fusion method, hot melt extrusion, spray drying, freeze drying and supercritical fluid precipitation, are reviewed in this paper. In addition, the physicochemical characteristics of the obtained solid dispersions are discussed.Expert opinion: Solid dispersions can be successfully prepared by simple fusion, hot melt extrusion, spray drying, freeze drying and supercritical fluid precipitation. Hot melt extrusion, spray drying and freeze drying are processes that can be applied for large scale production. The simple fusion method is not very suitable for large scale production, but is particularly suitable for screening formulations. The most recent method to produce sold dispersions is supercritical fluid precipitation. The process conditions of this method need extensive investigation, in particular in relationship with the selection of the type of carrier and/or solvent. Both processes and formulation aspects strongly affect the characteristics of solid dispersion products. Furthermore, application of crystalline solid dispersions is gaining increasing interest because they are thermodynamically more stable than amorphous solid dispersions.
KW - dissolution
KW - oral dosage form
KW - poorly water-soluble drugs
KW - solid dispersion
KW - HOT-MELT EXTRUSION
KW - SUPERCRITICAL CARBON-DIOXIDE
KW - WATER-SOLUBLE DRUGS
KW - TERTIARY BUTYL ALCOHOL
KW - DIFFERENTIAL SCANNING CALORIMETRY
KW - CONVENTIONAL SOLVENT EVAPORATION
KW - SPRAY-DRYING TECHNIQUE
KW - PHYSICOCHEMICAL CHARACTERIZATION
KW - POLYETHYLENE-GLYCOL
KW - BIOAVAILABILITY ENHANCEMENT
U2 - 10.1517/17425247.2011.598147
DO - 10.1517/17425247.2011.598147
M3 - Review article
C2 - 21722000
SN - 1742-5247
VL - 8
SP - 1121
EP - 1140
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 9
ER -